← Retour à la une
États-Unis · Plateformes & données · Yahoo Finance

Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference

Publié par Yahoo Finance · États-Unis il y a 9 h
ACCESS Newswire · Vicore Pharma Holding
ACCESS Newswire · Vicore Pharma Holding · Yahoo Finance

Résumé détaillé

STOCKHOLM, SE / ACCESS Newswire / / AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists,…

STOCKHOLM, SE / ACCESS Newswire / November 17, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the DNB Carnegie Nordic Healthcare Conference.

Panel: Idiopathic Pulmonary Fibrosis | Three shots at reversing IPF - the Nordic fibrosis race

For further information, please contact:Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding ABVicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

AttachmentsVicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi